Diligence memo · auto-generated · as of July 2, 2026
Dnanexus, Inc.
Dnanexus, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Dnanexus, Inc. operates in Biotechnology, based in MOUNTAIN VIEW.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Dnanexus, Inc. has raised $32M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $15M on 2013-12-20.
Most recent recorded round closed around 2015-04-16.
Valuation (modeled)modeled
Provath models Dnanexus, Inc. at approximately $542M (range $16M–$2.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 3.41× the median modeled value of Series A Biotechnology companies in 2013–2015 (111 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 36 months.
Last raise 11.2 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 75% of Biotechnology peers (4293 compared).
Modeled value ranks above 84% of those peers.
Closest niche peers: Foresight Biotherapeutics, Inc., AuraSense Therapeutics, LLC, Zyomyx Inc, Champions Oncology, Inc., Thrasos Innovation Inc..
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.